MedTrace Logo

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

NCT03399513 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-01-05

No results posted yet for this study

Summary

This study will investigate if treatment results obtained with R-CHOEP in young high-risk patients with diffuse large B-cell lymphoma can be further improved by the addition of ibrutinib to this regimen.

Conditions

Interventions

DRUG

Ibrutinib Oral Capsule [Imbruvica]

Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)

DRUG

R-CHOEP chemotherapy

Immunochemotherapy

Sponsors & Collaborators

  • Janssen-Cilag G.m.b.H

    collaborator INDUSTRY

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Prof. Norbert Schmitz, MD · University Hospital Muenster

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-03
Primary Completion
2023-12-23
Completion
2023-12-23

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03399513 on ClinicalTrials.gov